Vanderbilt-Ingram Cancer Center

Vanderbilt-Ingram website >

Twenty-four hours after the administration of the study drug, catheters are inserted into the tumor and lasers emitting a wavelength of light that activates the dye molecule on the ASP-1929 are illuminated.
October 14, 2021

Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer

Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.

By Tom Wilemon
September 30, 2021

Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription

Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.

By Tom Wilemon
September 23, 2021

Clinical trial tests ATR inhibitor in difficult-to-treat cancers

By Doug Campbell
September 23, 2021

Eng named co-chair of NCI clinical trials steering committee

Vanderbilt’s Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.

By Tom Wilemon
September 16, 2021

Structural variants in breast cancer risk genes

Vanderbilt epidemiologists conducted in-depth whole genome sequencing of breast cancer risk genes in Black women, who die at higher rates and have more aggressive disease, to discover mutations that may improve testing and treatment selection.

By Leigh MacMillan
September 10, 2021

Novel immunotherapy shows robust response for multiple myeloma

Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.

By Tom Wilemon
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
By Bill Snyder
August 19, 2021

Expression atlas for cell regulators

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.
By Leigh MacMillan
August 19, 2021

Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).
By Tom Wilemon
August 19, 2021

Supporting ovarian cancer research

Rocker George Thorogood recently made a donation to Vanderbilt-Ingram Cancer Center (VICC) from the Marla Thorogood Memorial Fund for Ovarian Cancer Research.
By VUMC News and Communications
August 19, 2021

Jackson elected fellow of American Association of Nurse Practitioners

Heather Jackson, PhD, APRN, administrative director of Advanced Practice for Vanderbilt-Ingram Cancer Center, has been elected a fellow of the American Association of Nurse Practitioners.
By Matt Batcheldor
August 5, 2021

Clinical trial to test immunotherapy for rectal cancer

A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.
By Tom Wilemon
July 15, 2021

Ciombor chosen for NCI clinical investigator team leadership award

Kristen Ciombor, MD, MSCI, is one of 10 physicians nationwide selected by the National Cancer Institute (NCI) for the 2021 Cancer Clinical Investigator Team Leadership Award.
By Tom Wilemon
1 … 16 17 18 19 20 … 28